WallStSmart

Edwards Lifesciences Corp (EW)vsINVO Fertility, Inc. (IVF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 86372% more annual revenue ($6.51B vs $7.53M). EW leads profitability with a 15.4% profit margin vs -70.2%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48

IVF

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -6.79
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+68.9%)

Margin of Safety

+68.9%

Fair Value

$254.99

Current Price

$84.37

$170.62 discount

UndervaluedFair: $254.99Overvalued

Intrinsic value data unavailable for IVF.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

IVF3 strengths · Avg: 9.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
51.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

IVF4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.53M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-1.29M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bull Case : IVF

The strongest argument for IVF centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.

Bear Case : IVF

The primary concerns for IVF are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

EW profiles as a mature stock while IVF is a growth play — different risk/reward profiles.

IVF is growing revenue faster at 16.7% — sustainability is the question.

EW generates stronger free cash flow (585M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EW scores higher overall (55/100 vs 38/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

INVO Fertility, Inc.

HEALTHCARE · MEDICAL DEVICES · USA

INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. The company is headquartered in Sarasota, Florida.

Want to dig deeper into these stocks?